Anthracyclines and early breast cancer: The end of an era?

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1155-1157

  Gianni, Luca ^a   Valagussa, Pinuccia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Fondazione Michelangelo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EARLY CANCER; EDITORIAL; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART DEATH; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PRIORITY JOURNAL; TOP2A GENE; TUMOR GENE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 62549160897     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1640     Document Type: Editorial

References (26)

1. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results. JAMA 273:542-547, 1995
2. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
3. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
4. Francis P, Crown J, Di Leo A, etal: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133, 2008
5. Gianni L, Baselga J, Eiermann W, et al: European Cooperative Trial in Operative Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 23:7s, 2005 (suppl; abstr 513)
6. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
7. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741 /Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
8. Jones SE, Holmes FA, ÓShaughnessy JA, et al: Docetaxel with cyclo phosphamide is associated with an overall survival benefit compared to doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
9. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxoru-bicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
10. Pritchard Kl, Messersmith H, Elavathil L, et al: HEFi-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736-744, 2008
11. Lachin JM: Statistical considerations in the intent-to-treat principle. Control Clin Trials 21:167-189, 2000
12. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
13. Levine MN, Pritchard Kl, Bramwell VH, et al: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170, 2005
14. Bonneterre J, Roché H, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693, 2005
15. Early Breast Cancer Trialistś Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
16. Poole CJ, Earl HM, Hiller L, et al: NEAT Investigators and the SCTBG: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006
17. Martin M, Rodriguez-Lescure A, Ruiz A, et al: GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophos-phamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814, 2008
18. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006
19. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
20. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
21. Bartlett JM, Munro A, Cameron DA, et al: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26:5027-5035, 2008
22. Slamon D, Eiermann W, Robert N, et al: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: Second interim efficacy analysis. Presented at the San Antonio Breast Cancer meeting, San Antonio, TX, December 14-17, 2006
23. Minotti G, Menna P, Salvatorelli E, et al: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229, 2004
24. Slamon DJ, Mackey J, Robert N, et al: Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. Breast Cancer Res Treat 106:1s, 2007 (suppl1; abstr 13)
25. Gianni L, Herman EH, Lipshultz SE, et al: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784, 2008
26. Bianchini G, Gianni L: Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? Ann Oncol 19:vii177-vii183, 2008 (suppl 7)